- Home
- ANGO vs KIO Comparison
ANGO vs KIO Comparison
Compare ANGO & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANGO | KIO |
|---|---|---|
| Founded | 1988 | N/A |
| Country | United States | United States |
| Employees | N/A | 2400 |
| Industry | Medical/Dental Instruments | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.2M | 461.1M |
| IPO Year | 2004 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ANGO | KIO |
|---|---|---|
| Price | $12.18 | $11.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $18.00 | N/A |
| AVG Volume (30 Days) | ★ 276.5K | 139.3K |
| Earning Date | 04-02-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $291,010,000.00 | N/A |
| Revenue This Year | $9.51 | N/A |
| Revenue Next Year | $4.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.17 | N/A |
| 52 Week Low | $8.36 | $10.65 |
| 52 Week High | $13.99 | $12.83 |
Technical Indicators
Market Signals| Indicator | ANGO | KIO |
|---|---|---|
| Relative Strength Index (RSI) | 61.18 | 51.56 |
| Support Level | $10.45 | $10.66 |
| Resistance Level | $12.72 | $11.45 |
| Average True Range (ATR) | 0.39 | 0.11 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 79.04 | 59.76 |
Price Performance
Historical ComparisonAbout ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.